Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1322600

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

Description:
Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Flamel Technologies S.A. (Flamel) is a specialty pharmaceutical company which conducts the development of drugs to tackle unmet medical needs. The company utilizes its proprietary drug delivery technologies platforms, namely, Medusa, LiquiTime, Micropump, and Trigger Lock to develop new chemical entities (NCEs) and new biological entities (NBEs). Flamel’s flagship product, Bloxiverz (neostigmine methylsulfate injection) is an intravenous drug used in operating rooms for reversal of the effects of non-depolarizing neuromuscular blocking agents post surgery.

Flamel Technologies S.A. Key Recent Developments

Apr 29, 2014: Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Oct 31, 2013: Flamel Technologies Announces Third Quarter 2013 Results
Oct 17, 2013: Flamel Technologies Announces Projected Release Date of Third Quarter 2013 Results and Conference Call
Sep 11, 2013: Flamel Technologies Announces Acceptance of FDA Review for Second NDA
Jul 29, 2013: Flamel Technologies Announces Second Quarter 2013 Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 
Contents:
Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 - About the Company
Flamel Technologies S.A. - Key Facts
Flamel Technologies S.A. - Key Employees
Flamel Technologies S.A. - Key Employee Biographies
Flamel Technologies S.A. - Major Products and Services
Flamel Technologies S.A. - Pharmaceutical Pipeline Products Data
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A. - History
Flamel Technologies S.A. - Company Statement
Flamel Technologies S.A. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Flamel Technologies S.A. - Key Manufacturing Facilities
Section 2 – Company Analysis
Flamel Technologies S.A. - Business Description
Flamel Technologies S.A. - SWOT Analysis
SWOT Analysis - Overview
Flamel Technologies S.A. - Strengths
Strength - Coreg CR-Lead product
Strength - Unique Polymer-Based Drug Delivery Platforms
Strength - Successful Integration of Eclat Pharmaceuticals LLC
Flamel Technologies S.A. - Weaknesses
Weakness - Declining Profitability
Weakness - Complete Response Letter
Weakness - Dependence on Limited Customer Base
Flamel Technologies S.A. - Opportunities
Opportunity - Need for Novel Delivery Systems
Opportunity - New product Launches
Opportunity - Potential Market for Cardiovascular Drugs
Flamel Technologies S.A. - Threats
Threat - Increasing Parallel Trade
Threat - Uncertain R&D Outcomes
Threat - Intense Competition
Flamel Technologies S.A. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Flamel Technologies S.A., Recent Deals Summary
Section 5 – Company’s Recent Developments
Flamel Technologies S.A., Recent Developments
Apr 29, 2014: Flamel Technologies Announces Receipt of Complete Response Letter From FDA Citing Issues at the Facility of the Supplier of the Active Ingredient
Oct 31, 2013: Flamel Technologies Announces Third Quarter 2013 Results
Oct 17, 2013: Flamel Technologies Announces Projected Release Date of Third Quarter 2013 Results and Conference Call
Sep 11, 2013: Flamel Technologies Announces Acceptance of FDA Review for Second NDA
Jul 29, 2013: Flamel Technologies Announces Second Quarter 2013 Results
Jul 01, 2013: Flamel Technologies Announces Resubmission of Second NDA
Jun 24, 2013: Flamel Technologies Announces Results of 2013 Annual Meeting
May 07, 2013: Flamel Technologies Reports Revenue Of $5.1m In Q1 2013
Mar 22, 2013: US District Court Dismisses Class Action Case Against Flamel Technologies
Feb 28, 2013: Flamel Technologies Reports Revenue Of $26.1m In 2012
Section 6 – Appendix
Methodology
Ratio Definitions
About Us
Contact Us
Disclaimer

List of Tables
Flamel Technologies S.A., Key Facts
Flamel Technologies S.A., Key Employees
Flamel Technologies S.A., Key Employee Biographies
Flamel Technologies S.A., Major Products and Services
Flamel Technologies S.A., Number of Pipeline Products by Therapy Area
Flamel Technologies S.A., Number of Pipeline Products by Development Stage
Flamel Technologies S.A., Pipeline Products By Therapy Area and Development Phase
Flamel Technologies S.A., History
Flamel Technologies S.A., Subsidiaries
Flamel Technologies S.A., Key Manufacturing Facilities
Flamel Technologies S.A., Key Competitors
Flamel Technologies S.A., Ratios based on current share price
Flamel Technologies S.A., Annual Ratios
Flamel Technologies S.A., Interim Ratios
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Type, 2008 to YTD 2014
Flamel Technologies S.A., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Flamel Technologies S.A., Pipeline Products by Therapy Area
Flamel Technologies S.A., Pipeline Products by Development Phase
Flamel Technologies S.A., Performance Chart (2008 - 2012)
Flamel Technologies S.A., Ratio Charts
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014
Flamel Technologies S.A., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014
 
Companies Mentioned
Enzon Pharmaceuticals, Inc.
ANDRX Corporation
Ambrx, Inc.
DURECT Corporation
Nektar Therapeutics
Human Genome Sciences, Inc.
Depomed, Inc.
SkyePharma PLC
Alkermes, Inc.
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1322600

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Sep 17th 2014
7:27:36 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Flamel Technologies S.A. (FLML) - Financial and Strategic SWOT Analysis Review

Web Address

http://www.researchandmarkets.com/reports/1322600

Office Code

OCGOOGLE

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User USD 125
Electronic (PDF) - Site License USD 250
Electronic (PDF) - Enterprisewide USD 375

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Sep 17th 2014
7:27:36 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)